Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 May;206(5):1390-1396.
doi: 10.1111/bjh.20012. Epub 2025 Feb 26.

Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents

Sara Mato  1   2 , Lorenzo Carità  1 , Ariadna Colmenero  1   2 , Mara Andrés  3 , Olga Balagué  4   5 , Maitane Andión  6 , Itziar Astigarraga  7   8 , Verónica Celis  9 , Carmen Mendoza  10 , Pilar Guerra-García  11 , Lorena Valero  12 , Ana Galera  13 , María Tallón  14 , Melina Pol  1 , Natalia Castrejón-de-Anta  2   4 , Leonie Frauenfeld  1 , Noelia Garcia  1 , Elías Campo  1   2   4   5 , Itziar Salaverria  1   5 , Jaime Verdú-Amorós  5   15
Affiliations

Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents

Sara Mato et al. Br J Haematol. 2025 May.

Abstract

The outcome of B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents has improved significantly over recent decades due to risk-adapted strategies and the use of immunotherapy. However, refractory or relapsed (R/R) B-NHL remains extremely difficult to cure (<30%). This retrospective study of 45 patients with R/R B-NHL reflects the limited benefit associated with reintroducing rituximab in second-line strategies, the importance of achieving complete remission before stem cell transplantation and the potential role of TP53 as a biomarker in R/R B-NHL. TP53 mutations were identified in 44% of tumours and associated with a worse 3-year overall survival (15% vs. 80%; p = 0.048).

Keywords: TP53; Burkitt lymphoma; NHL; paediatric lymphoma; refractory; relapse.

PubMed Disclaimer

References

REFERENCES

    1. Minard‐Colin V, Aupérin A, Pillon M, Burke GAA, Barkauskas DA, Wheatley K, et al. Rituximab for high‐risk, mature B‐cell non‐Hodgkin's lymphoma in children. N Engl J Med. 2020;382:2207–2219.
    1. Amos Burke GA, Minard‐Colin V, Aupérin A, Alexander S, Pillon M, Delgado R, et al. Dose‐adjusted etoposide, doxorubicin, and cyclophosphamide with vincristine and prednisone plus rituximab therapy in children and adolescents with primary mediastinal B‐cell lymphoma: a multicenter phase II trial. J Clin Oncol. 2021;39:3716–3724.
    1. Woessmann W, Zimmermann M, Meinhardt A, Müller S, Hauch H, Knörr F, et al. Progressive or relapsed Burkitt lymphoma or leukemia in children and adolescents after BFM‐type first‐line therapy. Blood. 2020;135:1124–1132.
    1. Jourdain A, Auperin A, Minard‐Colin V, Aladjidi N, Zsiros J, Coze C, et al. Outcome of and prognostic factors for relapse in children and adolescents with mature B‐cell lymphoma and leukemia treated in three consecutive prospective “Lymphomes Malins B” protocols. A Société Française des Cancers de l'Enfant study. Haematologica. 2015;100:810–817.
    1. Rosolen A, Perkins SL, Pinkerton CR, Guillerman RP, Sandlund JT, Patte C, et al. Revised international pediatric non‐Hodgkin lymphoma staging system. J Clin Oncol. 2015;33:2112–2118.

LinkOut - more resources